Molecular modeling strategy for detailing the primary mechanism of action of copanlisib to PI3K: combined ligand-based and target-based approach

References

• Bandarage, U. K., Aronov, A. M., Cao, J., Come, J. H., Cottrell, K. M., Davies, R. J., Giroux, S., Jacobs, M., Mahajan, S., Messersmith, D., Moody, C. S., Swett, R., & Xu, J. (2021). Discovery of a novel series of potent and selective alkynylthiazole-derived PI3Kgamma inhibitors. ACS Medicinal Chemistry Letters, 12(1), 129–135. https://doi.org/10.1021/acsmedchemlett.0c00573
   PubMed Web of Science ®Google Scholar
• Bheemanaboina, R. R. Y. (2020). Isoform-selective PI3K inhibitors for various diseases. Current Topics in Medicinal Chemistry, 20(12), 1074–1092. https://doi.org/10.2174/1568026620666200106141717
   PubMed Web of Science ®Google Scholar
• Certal, V., Carry, J.-C., Halley, F., Virone-Oddos, A., Thompson, F., Filoche-Rommé, B., El-Ahmad, Y., Karlsson, A., Charrier, V., Delorme, C., Rak, A., Abecassis, P.-Y., Amara, C., Vincent, L., Bonnevaux, H., Nicolas, J.-P., Mathieu, M., Bertrand, T., Marquette, J.-P., … Schio, L. (2014). Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. Journal of Medicinal Chemistry, 57(3), 903–920. https://doi.org/10.1021/jm401642q
   PubMed Web of Science ®Google Scholar
• Cheson, B. D., O'Brien, S., Ewer, M. S., Goncalves, M. D., Farooki, A., Lenz, G., Yu, A., Fisher, R. I., Zinzani, P. L., & Dreyling, M. (2019). Optimal management of adverse events from copanlisib in the treatment of patients with non-hodgkin lymphomas. Clinical Lymphoma, Myeloma & Leukemia, 19(3), 135–141. https://doi.org/10.1016/j.clml.2018.11.021
   PubMed Web of Science ®Google Scholar
• Fradera, X., Methot, J. L., Achab, A., Christopher, M., Altman, M. D., Zhou, H., McGowan, M. A., Kattar, S. D., Wilson, K., Garcia, Y., Augustin, M. A., Lesburg, C. A., Shah, S., Goldenblatt, P., & Katz, J. D. (2019). Design of selective PI3Kdelta inhibitors using an iterative scaffold-hopping workflow. Bioorganic & Medicinal Chemistry Letters, 29(18), 2575–2580. https://doi.org/10.1016/j.bmcl.2019.08.004
   PubMed Web of Science ®Google Scholar
• Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017). The PI3K pathway in human disease. Cell, 170(4), 605–635. https://doi.org/10.1016/j.cell.2017.07.029
   PubMed Web of Science ®Google Scholar
• Fu, Y., Sun, Y. N., Yi, K. H., Li, M. Q., Cao, H. F., Li, J. Z., & Ye, F. (2017). 3D Pharmacophore-based virtual screening and docking approaches toward the discovery of novel HPPD inhibitors. Molecules, 22(6), 959. https://doi.org/10.3390/molecules22060959
   PubMed Web of Science ®Google Scholar
• Jia, L., Wang, L., Jiang, Y., Xu, L., Cai, Y., Chen, Y., Jin, J., Sun, H., & Zhu, J. (2022). Exploring PI3Kgamma binding preference with Eganelisib, Duvelisib, and Idelalisib via energetic, pharmacophore and dissociation pathway analyses. Computers in Biology and Medicine, 147, 105642. https://doi.org/10.1016/j.compbiomed.2022.105642
   PubMed Web of Science ®Google Scholar
• Jiang, Y., Xiong, W., Jia, L., Xu, L., Cai, Y., Chen, Y., Jin, J., Gao, M., & Zhu, J. (2022). Developing a Naive Bayesian Classification Model with PI3Kgamma structural features for virtual screening against PI3Kgamma: Combining molecular docking and pharmacophore based on multiple PI3Kgamma conformations. European Journal of Medicinal Chemistry, 244, 114824. https://doi.org/10.1016/j.ejmech.2022.114824
   PubMed Web of Science ®Google Scholar
• Klepeis, J. L., Lindorff-Larsen, K., Dror, R. O., & Shaw, D. E. (2009). Long-timescale molecular dynamics simulations of protein structure and function. Current Opinion in Structural Biology, 19(2), 120–127. https://doi.org/10.1016/j.sbi.2009.03.004
   PubMed Web of Science ®Google Scholar
• Lanahan, S. M., Wymann, M. P., & Lucas, C. L. (2022). The role of PI3Kgamma in the immune system: New insights and translational implications. Nature Reviews. Immunology, 22(11), 687–700. https://doi.org/10.1038/s41577-022-00701-8
   PubMed Web of Science ®Google Scholar
• Le, T., Jerel, D., & Bryan, L. J. (2021). Update on the role of copanlisib in hematologic malignancies. Therapeutic Advances in Hematology, 12, 20406207211006027. https://doi.org/10.1177/20406207211006027
   Web of Science ®Google Scholar
• Li, K., Zhu, J. Y., Xu, L., & Jin, J. (2019). Rational design of novel phosphoinositide 3-kinase gamma (PI3K gamma) selective inhibitors: a computational investigation integrating 3D-QSAR, molecular docking and molecular dynamics simulation. Chemistry and Biodiversity. 16(7), e1900105. https://doi.org/10.1002/cbdv.201900105
   PubMed Web of Science ®Google Scholar
• Liu, J., Zhu, Y., He, Y., Zhu, H., Gao, Y., Li, Z., Zhu, J., Sun, X., Fang, F., Wen, H., & Li, W. (2020). Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing. Journal of Biomolecular Structure & Dynamics, 38(2), 533–547. https://doi.org/10.1080/07391102.2019.1590241
   PubMed Web of Science ®Google Scholar
• Meng, D., He, W., Zhang, Y., Liang, Z., Zheng, J., Zhang, X., Zheng, X., Zhan, P., Chen, H., Li, W., & Cai, L. (2021). Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review). Pharmacological Research, 173, 105900. https://doi.org/10.1016/j.phrs.2021.105900
   PubMed Web of Science ®Google Scholar
• Mensah, F. A., Blaize, J. P., & Bryan, L. J. (2018). Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: Evidence to date. OncoTargets and Therapy, 11, 4817–4827. https://doi.org/10.2147/OTT.S142264
   PubMed Web of Science ®Google Scholar
• Mohamed, A. R., & El Kerdawy, A. M. (2022). A perspective study on the RTK, PI3K, B-Raf, CDK and the multi-protein targeting in medicinal chemistry. Chemistry & Biodiversity, 19(10), e202200328. https://doi.org/10.1002/cbdv.202200328
   PubMed Web of Science ®Google Scholar
• Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012). Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. Journal of Medicinal Chemistry, 55(14), 6582–6594. https://doi.org/10.1021/jm300687e
   PubMed Web of Science ®Google Scholar
• Perry, M. W. D., Björhall, K., Bold, P., Brűlls, M., Börjesson, U., Carlsson, J., Chang, H.-F A., Chen, Y., Eriksson, A., Fihn, B.-M., Fransson, R., Fredlund, L., Ge, H., Huang, H., Karabelas, K., Lamm Bergström, E., Lever, S., Lindmark, H., Mogemark, M., … Öster, L. (2021). Discovery of AZD8154, a dual PI3Kgammadelta inhibitor for the treatment of asthma. Journal of Medicinal Chemistry, 64(12), 8053–8075. https://doi.org/10.1021/acs.jmedchem.1c00434
   PubMed Web of Science ®Google Scholar
• Rathinaswamy, M. K., Gaieb, Z., Fleming, K. D., Borsari, C., Harris, N. J., Moeller, B. E., Wymann, M. P., Amaro, R. E., & Burke, J. E. (2021). Disease-related mutations in PI3Kgamma disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. Elife, 10, e64691. https://doi.org/10.7554/eLife.64691
   PubMed Web of Science ®Google Scholar
• Robustelli, P., Piana, S., & Shaw, D. E. (2018). Developing a molecular dynamics force field for both folded and disordered protein states. Proceedings of the National Academy of Sciences of the United States of America, 115(21), E4758–E4766. https://doi.org/10.1073/pnas.1800690115
   PubMed Web of Science ®Google Scholar
• Roskoski, R. Jr (2021). Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. Pharmacological Research, 168, 105579. https://doi.org/10.1016/j.phrs.2021.105579
   PubMed Web of Science ®Google Scholar
• Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2021). Phosphatidylinositol 3-kinase (PI3K) inhibitors: A recent update on inhibitor design and clinical trials (2016-2020). Expert Opinion on Therapeutic Patents, 31(10), 877–892. https://doi.org/10.1080/13543776.2021.1924150
   PubMed Web of Science ®Google Scholar
• Scott, W. J., Hentemann, M. F., Rowley, R. B., Bull, C. O., Jenkins, S., Bullion, A. M., Johnson, J., Redman, A., Robbins, A. H., Esler, W., Fracasso, R. P., Garrison, T., Hamilton, M., Michels, M., Wood, J. E., Wilkie, D. P., Xiao, H., Levy, J., Stasik, E., … Lefranc, J. (2016). Discovery and SAR of novel 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: identification of copanlisib (BAY 80-6946). ChemMedChem. 11(14), 1517–1530. https://doi.org/10.1002/cmdc.201600148
   PubMed Web of Science ®Google Scholar
• Shaikh, N., Linthoi, R. K., Swamy, K. V., Karthikeyan, M., & Vyas, R. (2022). Comprehensive molecular docking and dynamic simulations for drug repurposing of clinical drugs against multiple cancer kinase targets. Journal of Biomolecular Structure & Dynamics, 22, 1–9. https://doi.org/10.1080/07391102.2022.2124453
   Google Scholar
• Thakur, A., Tawa, G. J., Henderson, M. J., Danchik, C., Liu, S., Shah, P., Wang, A. Q., Dunn, G., Kabir, M., Padilha, E. C., Xu, X., Simeonov, A., Kharbanda, S., Stone, R., & Grewal, G. (2020). Design, synthesis, and biological evaluation of quinazolin-4-one-based hydroxamic acids as Dual PI3K/HDAC inhibitors. Journal of Medicinal Chemistry, 63(8), 4256–4292. https://doi.org/10.1021/acs.jmedchem.0c00193
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., Andre, F., & Okkenhaug, K. (2021). PI3K inhibitors are finally coming of age. Nature Reviews. Drug Discovery, 20(10), 741–769. https://doi.org/10.1038/s41573-021-00209-1
   PubMed Web of Science ®Google Scholar
• Xiong, G., Wu, Z., Yi, J., Fu, L., Yang, Z., Hsieh, C., Yin, M., Zeng, X., Wu, C., Lu, A., Chen, X., Hou, T., & Cao, D. (2021). ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Research, 49(W1), W5–W14. https://doi.org/10.1093/nar/gkab255
   PubMed Web of Science ®Google Scholar
• Xiong, W., Jia, L., Liang, J., Cai, Y., Chen, Y., Nie, Y., Jin, J., & Zhu, J. (2022). Investigation into the anti-airway inflammatory role of the PI3Kgamma inhibitor JN-PK1: An in vitro and in vivo study. International Immunopharmacology, 111, 109102. https://doi.org/10.1016/j.intimp.2022.109102
   PubMed Web of Science ®Google Scholar
• Xu, C., Chen, S., Deng, Y., Song, J., Li, J., Chen, X., Chang, P., Yao, L., & Tang, H. (2021). Distinct roles of PI3Kdelta and PI3Kgamma in a toluene diisocyanate-induced murine asthma model. Toxicology, 454, 152747. https://doi.org/10.1016/j.tox.2021.152747
   PubMedGoogle Scholar
• Yu, L., Jiang, Y., Xu, L., Jin, J., Pei, Z., & Zhu, J. (2022). Theoretical study of myriocin-binding mechanism targeting serine palmitoyltransferase. Chemical Biology & Drug Design, 99(3), 373–381. https://doi.org/10.1111/cbdd.13991
   PubMed Web of Science ®Google Scholar
• Yu, M., Gu, Q., & Xu, J. (2018). Discovering new PI3Kalpha inhibitors with a strategy of combining ligand-based and structure-based virtual screening. Journal of Computer-Aided Molecular Design, 32(2), 347–361. https://doi.org/10.1007/s10822-017-0092-8
   PubMed Web of Science ®Google Scholar
• Zhang, X., Vadas, O., Perisic, O., Anderson, K. E., Clark, J., Hawkins, P. T., Stephens, L. R., & Williams, R. L. (2011). Structure of lipid kinase p110beta/p85beta elucidates an unusual SH2-domain-mediated inhibitory mechanism. Molecular Cell, 41(5), 567–578. https://doi.org/10.1016/j.molcel.2011.01.026
   PubMed Web of Science ®Google Scholar
• Zhu, J. Y., Jia, L., Jiang, Y. M., Yu, Q. Q., Xu, L., Cai, Y. F., Chen, Y., Li, H. Z., Gang, H., Liang, W. Q., & Jin, J. (2021b). Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3K delta with marketed Idelalisib. Chemical Biology & Drug Design, 97(6), 1158–1169. https://doi.org/10.1111/cbdd.13838
   PubMed Web of Science ®Google Scholar
• Zhu, J. Y., Wu, Y. Q., Wang, M., Li, K., Xu, L., Chen, Y., Cai, Y. F., & Jin, J. (2020a). Integrating machine learning-based virtual screening with multiple protein structures and bio-assay evaluation for discovery of novel GSK3 beta inhibitors. Frontiers in Pharmacology, 11, 566058. https://doi.org/10.3389/fphar.2020.566058
   PubMed Web of Science ®Google Scholar
• Zhu, J. Y., Yu, Q. Q., Cai, Y. F., Chen, Y., Liu, H., Liang, W. Q., & Jin, J. (2020b). Theoretical exploring selective-binding mechanisms of JAK3 by 3D-QSAR, molecular dynamics simulation and free energy calculation. Frontiers in Molecular Biosciences, 7, 83. https://doi.org/10.3389/fmolb.2020.00083
   PubMed Web of Science ®Google Scholar
• Zhu, J. Y., Zhang, H., Yu, L., Sun, H. Y., Chen, Y., Cai, Y. F., Li, H. Z., & Jin, J. (2021c). Computational investigation of the selectivity mechanisms of PI3K delta inhibition with marketed idelalisib: Combined molecular dynamics simulation and free energy calculation. Structural Chemistry, 32(2), 699–707. https://doi.org/10.1007/s11224-020-01643-4
   Web of Science ®Google Scholar
• Zhu, J., Hou, T., & Mao, X. (2015). Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. Drug Discovery Today, 20(8), 988–994. https://doi.org/10.1016/j.drudis.2015.03.009
   PubMed Web of Science ®Google Scholar
• Zhu, J., Li, K., Xu, L., Cai, Y., Chen, Y., Zhao, X., Li, H., Huang, G., & Jin, J. (2022). Discovery of novel selective PI3Kgamma inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation. Journal of Advanced Research, 36, 1–13. https://doi.org/10.1016/j.jare.2021.04.007
   PubMed Web of Science ®Google Scholar
• Zhu, J., Li, K., Yu, L., Chen, Y., Cai, Y., Jin, J., & Hou, T. (2021a). Targeting phosphatidylinositol 3-kinase gamma (PI3Kgamma): Discovery and development of its selective inhibitors. Medicinal Research Reviews, 41(3), 1599–1621. https://doi.org/10.1002/med.21770
   PubMed Web of Science ®Google Scholar
• Zhu, J., Wang, M., Cao, B., Hou, T., & Mao, X. (2014). Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma. Current Medicinal Chemistry, 21(27), 3173–3187. https://doi.org/10.2174/0929867321666140601204513
   PubMed Web of Science ®Google Scholar